Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00574925
Recruitment Status : Completed
First Posted : December 17, 2007
Last Update Posted : December 18, 2007
Sponsor:
Collaborator:
AstraZeneca
Information provided by:
University of Zurich

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The primary objective of this study is to investigate whether eradication treatment of Helicobacter pylori followed by therapy with esomeprazole for a total of 8 weeks extends the time to relapse in patients with gastroesophageal reflux disease (GERD).

A relapse is defined by two consecutive symptom scores of the Eraflux questionnaire within 14 days that are equal or above the critical value of 25.

The secondary objectives are

  1. To compare the time to relapse in the two H. pylori positive study groups with the H. pylori negative control group
  2. To compare the pattern of inflammation and atrophy in the two H. pylori positive treatment groups with the naturally H. pylori negative control group at relapse.
  3. All the above objectives analyzed for the efficacy subset that is the per-protocol patients broken down by effective H. pylori-eradication.

Secondary endpoints will be analyzed by the following parameters and their interactions:

  1. Treatment : Eradicated, Non-eradicated, Hp-negative control
  2. Esophagitis at study start: grades 0, A/B and C/D
  3. Gender
  4. Alcohol intake

  5. NSAID/ASA intake (for histological results)

    • Trial with medicinal product

Condition or disease Intervention/treatment Phase
Gastroesophageal Reflux Disease (GERD) Drug: Esomeprazole Phase 4

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients With Gastroesophageal Reflux Disease (GERD)
Study Start Date : November 2003
Study Completion Date : October 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: GERD

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

For inclusion in the study the subject must fulfill all of the following criteria:

  1. Patients aged between 18 and 70 years.
  2. Chronic symptoms (>8 weeks) suggestive for GERD, as defined in Table 2 with or without reflux esophagitis grade A-D (Los Angeles classification)
  3. Indication for endoscopy due to GERD symptoms is given
  4. Written informed consent

Table 2: Lead GERD criteria

For inclusion in the study, all of the following lead GERD criteria should hold:

  • At least one of the symptoms heartburn or regurgitation.
  • At least 8 weeks ongoing symptoms.
  • At least 3 times a week.
  • At least moderate intensity, corresponding to light impairment in daily life and occasional need for drugs.

Exclusion criteria:

Any of the following is regarded as a criterion for exclusion from the study:

  1. Severe organic esophageal disease other than reflux esophagitis (e.g. carcinoma, esophageal stenosis).
  2. Gastric or duodenal ulcers
  3. Patients with visible Barrett's mucosa; no histological confirmation is required for exclusion
  4. History of previous esophageal or gastric surgery
  5. Alcohol or drug abuse
  6. Severe organic or psychiatric disease
  7. Pregnancy or lactation
  8. Women with child-bearing potential if no medically accepted contraceptive measures are used
  9. Contra-indication to amoxicillin, clarithromycin or esomeprazole (Nexium)
  10. Need for concomitant medication which could interfere with the investigational products (substrates of CYP3A4)
  11. Suspected or confirmed poor compliance
  12. Participation in a clinical study within 8 weeks prior to enrollment.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00574925


Locations
Layout table for location information
Switzerland
University Hospital Zurich
Zurich, Switzerland
Sponsors and Collaborators
University of Zurich
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: Werner Schwizer, MD UniversitaetsSpital Zuerich
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00574925    
Other Study ID Numbers: ACH-QBE-0201
First Posted: December 17, 2007    Key Record Dates
Last Update Posted: December 18, 2007
Last Verified: December 2007
Keywords provided by University of Zurich:
H. pylori
Additional relevant MeSH terms:
Layout table for MeSH terms
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
 Esomeprazole
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action